<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387136</url>
  </required_header>
  <id_info>
    <org_study_id>ANES-2020-28605</org_study_id>
    <nct_id>NCT04387136</nct_id>
  </id_info>
  <brief_title>Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center</brief_title>
  <official_title>Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single dose of sublingual sufentanil given
      15-30 minutes prior to wake up is efficacious at reducing recovery room time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a level I randomized prospective outcomes study comparing two groups of patients.
      Within 15-30 minutes of planned wake-up Group 1 will receive 30 mcg of sublingual sufentanil
      and group 2 will not receive sublingual sufentanil.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Numeric Rating Scale (NRS) Pain Score upon Arrival</measure>
    <time_frame>2 hours</time_frame>
    <description>Pain is assessed on a scale of 0-10 (whole numbers). A score of 0 being no pain, 10 being maximum imaginable pain. Data collected upon arrival to Post-Anesthesia Care Unit (PACU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of time in Post-Anesthesia Care Unit (PACU)</measure>
    <time_frame>2 hours</time_frame>
    <description>Outcome reported as the mean length of time (in minutes) patients spend in Post-Anesthesia Care Unit (PACU) by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Use in Recovery Room</measure>
    <time_frame>2 hours</time_frame>
    <description>Opioid medication type and dose will be recorded and converted to milligram morphine equivalents. Outcome is reported as the total milligram morphine equivalents of opioid medication used in the recovery room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting (PONV)</measure>
    <time_frame>2 hours</time_frame>
    <description>Number of participants in each arm who are treated for nausea and/or vomiting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Numeric Rating Scale (NRS) Pain Score upon Discharge</measure>
    <time_frame>2 hours</time_frame>
    <description>Pain is assessed on a scale of 0-10 (whole numbers). A score of 0 being no pain, 10 being maximum imaginable pain. Data collected upon discharge from Post-Anesthesia Care Unit (PACU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain from Admission to Discharge</measure>
    <time_frame>2 hours</time_frame>
    <description>Pain is assessed on a scale of 0-10 (whole numbers). A score of 0 being no pain, 10 being maximum imaginable pain. Data collected upon arrival to and discharge from Post-Anesthesia Care Unit (PACU). Outcome is reported as the mean difference between both scores by arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OBAS Score</measure>
    <time_frame>2 hours</time_frame>
    <description>Overall Benefit of Analgesic Score (OBAS) is a 7-item multi-dimensional survey that assesses analgesia benefits. Items are scored on a scale from 0 (minimal) to 4 (maximal). Total score is a sum of the 7 item scores with question 7 scored as 4 minus the patient reported number. Total scores range from 0 to 28 with lower scores representing greater benefit from analgesic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesia Wake-up Time</measure>
    <time_frame>30 minutes</time_frame>
    <description>Anesthesia wake-up time is measured as the duration (in minutes) from procedure closure to removal of endotracheal tube or laryngeal mask airway.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain</condition>
  <condition>Pain, Acute</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sublingual Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will not receive an intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Sufentanil</intervention_name>
    <description>15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.</description>
    <arm_group_label>Sublingual Sufentanil</arm_group_label>
    <other_name>Dsuvia</other_name>
    <other_name>Sufenta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Adult patients undergoing outpatient ambulatory surgery undergoing general anesthesia for
        orthopedic surgery

        Exclusion Criteria:

          -  non-english speaking patients

          -  patients who have allergy or intolerance to the study drugs or derivatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Bern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aaron Berg, MD</last_name>
    <phone>612-624-9990</phone>
    <email>bergx831@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonah Pearson</last_name>
    <phone>612-625-6659</phone>
    <email>pears731@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Candace Nelson</last_name>
      <phone>612-626-2465</phone>
      <email>nelso377@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

